Harvard Bioscience Inc. announced a new retention agreement with Mark Frost, the company's Interim Chief Financial Officer, on August 12, 2025. Under the agreement, Mr. Frost is eligible for a $100,000 cash bonus upon the successful refinancing of the company's existing term loan and senior revolving credit facility by March 15, 2026. This bonus replaces the previously offered $50,000 bonus as per his offer letter dated April 10, 2025. If Mr. Frost is terminated without cause before the refinancing date, he will receive his base salary and the company's portion of COBRA premiums for five months, contingent upon signing a general release of claims.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。